Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?

This text was initially printed by . The title and a short excerpt are supplied for informational and reference functions. Readers ought to go to the unique writer for the entire article, supporting context, photos, and any subsequent updates.

Cathie Wooden, the CEO and founding father of Ark Funding Administration, owns, by her varied Ark ETFs, $220.4 million in Beam Therapeutics (NASDAQ: BEAM) shares. It’s a healthcare firm that focuses on gene enhancing to develop precision medicines.

She has owned shares in Beam…

The unique publication incorporates the entire reporting and needs to be consulted for the total textual content and any further data.

Classes: BEAM,LLY,PFE,ARKG,7e41bad5-76da-4e50-8309-3c87a52a975a,investing,Well being Care

Tags:

Read the Original Article →